ClinicalTrials.gg
CompletedNCT04262856ARC-7Updated Jun 15, 2026

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

A Phase 2 interventional study of Domvanalimab and Etrumadenant in Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer and Squamous Non Small Cell Lung Cancer, sponsored by Arcus Biosciences, Inc.. Completed at 44 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Arcus Biosciences, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 4 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jun 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing zimberelimab in Carcinoma, Non-Small-Cell Lung — 3 open to participants now, 6 under way, 2 of them phase 3. zimberelimab · Carcinoma, Non-Small-Cell Lung.

Enrollment
6th of 10
151 · median 152
Started
2020
the only one that year
Phase 2
4 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
4 of 10
Arcus Biosciences, Inc.

Among the 10 studies testing zimberelimab in Carcinoma, Non-Small-Cell Lung, this one is the 6th largest by enrollment, is the only one that started in 2020, is one of 4 in phase 2, and was the 3rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 10 studies testing zimberelimab in Carcinoma, Non-Small-Cell Lung are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About zimberelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing zimberelimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer.

03

Conditions studied

  • Non Small Cell Lung Cancer
  • Nonsquamous Non Small Cell Lung Cancer
  • Squamous Non Small Cell Lung Cancer
  • Lung Cancer

Keywords

  • Non Small Cell Lung Cancer
  • Lung Cancer
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants; age ≥ 18 years
  • confirmed, treatment naive, squamous or non-squamous NSCLC with documented high expression, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
  • (ECOG) performance status score of 0 or 1
  • Must have at least 1 per v1.1
  • Adequate organ and marrow function

Exclusion criteria

Exclusion Criteria:

  • Use of any against infectious diseases within 28 days of first dose of medicinal products (IMPs)
  • Any gastrointestinal condition that would preclude the use of oral medications (eg, difficulty swallowing, nausea, vomiting, or malabsorption)
  • History of trauma or major surgery within 28 days prior to the first dose of IMP
  • Concurrent medical condition requiring the use of supra-physiologic doses of (> 10 mg/day of oral prednisone or equivalent) or medications
  • Positive test results for surface antigen, virus antibody with presence of Hepatitis C qualitative RNA or (HIV-1 and/or HIV-2) antibody at screening
  • Any active disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy.
  • Prior active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate cancer
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Arm 1 (zimberelimab monotherapy)

    Participants will receive zimberelimab as an intravenous (IV) infusion.

    Drug: Zimberelimab

  • Experimental
    Arm 2 (domvanalimab and zimberelimab combination therapy)

    Participants will receive domvanalimab IV in combination with zimberelimab IV infusion.

    Drug: Domvanalimab · Drug: Zimberelimab

  • Experimental
    Arm 3 (domvanalimab, etrumadenant, and zimberelimab combination therapy)

    Participants will receive oral etrumadenant in combination with domvanalimab IV and zimberelimab IV infusion

    Drug: Domvanalimab · Drug: Etrumadenant · Drug: Zimberelimab

Interventions

  • Domvanalimab is a humanized monoclonal antibody targeting human TIGIT

    Also known as: AB154

  • Etrumadenant is an A2aR and A2bR antagonist

    Also known as: AB928

  • Zimberelimab is a fully human anti-PD-1 monoclonal antibody

    Also known as: AB122

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    ORR as assessed by RECIST v1.1

    Time frame: From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)

  2. Progression-free survival (PFS)

    PFS as assessed by RECIST v1.1

    Time frame: From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)

Secondary outcomes

  1. Duration of response (DoR)

    DoR as assessed by RECIST v1.1

    Time frame: From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)

  2. Disease control rate (DCR)

    DCR as assessed by RECIST v1.1

    Time frame: From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)

  3. Overall Survival (OS)

    OS as assessed at the time of PFS

    Time frame: From randomization to death from any cause (up to approximately 5 years)

  4. Number of Participants with Treatment Emergent Adverse Events (TEAEs)

    The number and percentage of participants that experience TEAE

    Time frame: From Screening until up to 90-100 days after the last dose (approximately 5 years)

  5. Pharmacokinetics of zimberelimab

    Serum concentration of zimberelimab as determined by validated assays

    Time frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)

  6. Pharmacokinetics of domvanalimab

    Serum concentration of domvanalimab as determined by validated assays

    Time frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)

  7. Pharmacokinetics of etrumadenant

    Serum concentration of etrumadenant as determined by validated assays

    Time frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)

  8. Immunogenicity of zimberelimab

    Percentage of participants who develop treatment-emergent anti-drug antibodies to zimberelimab

    Time frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, and 100 days post last dose (in total, an average of 2 years).

  9. Immunogenicity of domvanalimab

    Percentage of participants who develop treatment-emergent anti-drug antibodies to domvanalimab

    Time frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, and 100 days post last dose (in total, an average of 2 years).

07

Study locations

44 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Innovative Clinical Research Institute (ICRI)
    Whittier, California 90603, United States
  • Florida Cancer Specialists
    Englewood, Florida 34223, United States
  • Florida Cancer Specialists
    Gainesville, Florida 32605, United States
  • Florida Cancer Specialists - Panhandle
    Tallahassee, Florida 32308, United States
  • Florida Cancer Specialists - East
    West Palm Beach, Florida 33401, United States
  • Baptist Health Lexington
    Lexington, Kentucky 40503, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40202, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • The Valley Hospital - Valley Health System - The Robert and Audrey Luckow Pavilion
    Ridgewood, New Jersey 07450, United States
  • Clinical Research Alliance
    Lake Success, New York 11042, United States
  • Northwell Health Cancer Institute
    Lake Success, New York 11042, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • Allegheny General Hospital (AGH)-Alleghney Singer Research Institute
    Pittsburgh, Pennsylvania 15224, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • The Center For Cancer And Blood Disorders (Texas Cancer Care)
    Fort Worth, Texas 76104, United States
  • Millennium Oncology
    Houston, Texas 77339, United States
  • Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
    Blacksburg, Virginia 24060, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • Border Medical Oncology
    Albury, Australia
  • Coffs Harbour Health Campus
    Coffs Harbour, Australia
  • Adelaide Cancer Centre
    Elizabeth Vale, Australia
  • Shoalhaven Cancer Care Centre
    Nowra, Australia
  • McGill University Health Centre (MUHC) - The Montreal Children's Hospital (MCH)
    Montreal, Canada
  • Hong Kong United Oncology Centre
    Hong Kong, Hong Kong
  • Queen Elizabeth Hospital (Hong Kong)
    Hong Kong, Hong Kong
  • Curie Oncology
    Singapore, Singapore
  • Kosin University Gospel Hospital
    Busan, South Korea
  • Chungbuk National University Hospital (CBNUH)
    Cheongju-si, South Korea
  • Chonnam University Hospital
    Hwasun, South Korea
  • Gachon University Gil Medical Center
    Incheon, South Korea
  • Chonbuk National University Hospital
    Jeonju, South Korea
  • Seoul National University Bundang Hospital
    Seongnam-si, South Korea
  • Asan Medical Center
    Seoul, South Korea
  • Kangbuk Samsung Hospital
    Seoul, South Korea
  • Korea University Anam Hospital
    Seoul, South Korea
  • St Vincent Hospital of the Catholic University of Korea
    Suwon, South Korea
  • Catholic University of Korea, Uijeongbu St. Mary's Hospital
    Uijeongbu-si, South Korea
  • Taipei Medical University - Shuang Ho Hospital
    New Taipei City, Taiwan
  • Chi Mei Hospital
    Tainan, Taiwan
  • National Cheng Kung University Hospital
    Tainan, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan
  • Taipei Medical University Hospital
    Taipei, Taiwan
  • Chang Gung Memorial Hospital at Linkou
    Taoyuan, Taiwan
08

References and documents

Individual participant data

Plan to share: Yes — Arcus will provide access to individual de-identified participant data and related study documents (e.g., protocol, Statistical Analysis Plan [SAP], Clinical Study Report [CSR]) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. For more information, please visit our website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Data sharing details ↗ · trials.arcusbio.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Jul 2025, 61 months.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 61 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2020
First posted
Feb 10, 2020
StartActual
May 28, 2020
Primary completionActual
Jul 9, 2025
CompletionActual
Jul 9, 2025
Results delay requested
Jun 11, 2026
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04262856
Collaborators
Gilead Sciences
Responsible party
Sponsor
First posted
Feb 10, 2020
Start date
May 28, 2020
Primary completion
Jul 9, 2025
Completion
Jul 9, 2025
Last update
Jun 15, 2026

Study contacts

Medical Director
study director · Arcus Biosciences, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zimberelimab

Start the discussion